STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement

1. WildCVineisPGarteS 2008 Molecular Epidemiology of Chronic Diseases Chicester Wiley

2. VineisP 2004 Individual susceptibility to carcinogens. Oncogene 23 6477 6483

3. BonassiSAuWW 2002 Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res 511 73 86

4. MilikanR 2002 The changing face of epidemiology in the genomics era. Epidemiology 13 472 480

5. HunterDJ 1999 The future of molecular epidemiology. Int J Epidemiol 28 S1012 1014

6. RundleAGVineisPAhsanH 2005 Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 14 1899 1907

7. McShaneLMAltmanDGSauerbreiWTaubeSEGionM 2005 Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97 1180 1184

8. KyzasPADenaxa-KyzaDIoannidisJP 2007 Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43 2559 2579

9. BlairASaracciRVineisPCoccoPForastiereF Epidemiology, public health and the rhetoric of false positives. Environ Health Perspect 2009;117 1809 13

10. KyzasPALoizouKTIoannidisJP 2005 Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 14 1043 1055

11. IoannidisJPAPanagiotouO 2011 Comparison of effect sizes of biomarkers reported in highly-cited articles versus subsequent meta-analyses. JAMA 305 2200 2210

12. LumbrerasBParkerLAPortaMPollanMIoannidisJP 2009 Overinterpretation of clinical applicability in molecular diagnostic research. Clin Chem 55 786 794

13. IoannidisJPTaroneRMcLaughlinJK 2011 The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 22 450 456

14. SchulzKFAltmanDGMoherD CONSORT Group 2010 CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7 e1000251 doi:10.1371/journal.pmed.1000251

15. WhitingPFWeswoodMERutjesAWReitsmaJBBossuytPN 2003 The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included insystematic reviews. BMC Med Res Methodol 3 25

16. von ElmEAltmanDGEggerMPocockSJGotzschePC 2007 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4 e296 doi:10.1371/journal.pmed.0040296

17. VandenbrouckeJPvon ElmEAltmanDGGøtzschePCMulrowCD 2007 STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 4 e297 doi:10.1371/journal.pmed.0040297

18. FungAEPalankiRBakriSJDepperschmidtEGibsonA 2009 Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. Ophthalmology 116 286 296

19. Da CostaBCevallosMAltmanDRutjesAWEggerM 2010 Uses and misuses of the STROBE statement: bibliographic study. BMJ Open bmjopen-2010-000048 doi:10.1136/bmjopen-2010-000048

20. LittleJHigginsJPIoannidisJPMoherDGagnonF 2009 Strengthening the reporting of genetic association studies (STREGA)-an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol 62 597 608

21. CasteleynLDumezBJamersAVan DammeK Ethics and data protection in human biomarker studies. ECNIS Publications, Lodz, 2010

22. HainesDAArbuckleTELyeELegrandMFisherM 2011 Reporting results of human biomonitoring of environmental chemicals to study participants: a comparison of approaches followed in two Canadian studies. J Epidemiol Community Health 65 191 198

23. RansohoffDF 2004 Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4 309 314

24. PortaM 2008 A Dictionary of Epidemiology, 5th Ed New York Oxford University Press 21 69129–130, 152157–158

25. PortaMPumaregaJLópezTJariodMMarcoE 2009 Influence of tumor stage, symptoms and time of blood draw on serum concentrations of organochlorine compounds in exocrine pancreatic cancer. Cancer Causes Control 20 1893 1906

26. PortaMPumaregaJFerrer-ArmengouOLópezTAlguacilJ 2007 Timing of blood extraction in epidemiologic and proteomic studies. Results and proposals from the PANKRAS II Study. Eur J Epidemiol 22 577 588

27. RuchirawaMMahidolCTangjarukijCPuiockSJensenO 2002 Exposure to genotoxins present in ambient air in Bangkok, Thailand – particle associated polycyclic aromatic hydrocarbons and biomarkers. Sci Total Environ 287 121 132

28. SorensenMAutrupHHertelOWallinHKnudsenLE 2003 Personal exposure to PM2.5 and biomarkers of DNA damage. Cancer Epidemiol Biomarkers Prev 12 191 196

29. DusinskaMVallovaBUrsinyovaMHladikovaVSmolkovaB 2002 DNA damage and antioxidants; fluctuations through the year in a central European population group. Food Chem Toxicol 40 1119 1123

30. GiovannelliLSaievaCMasalaGTestaGSalviniS 2002 Nutritional and lifestyle determinants of DNA oxidative damage: a study in a Mediterranean population. Carcinogenesis 23 1483

31. MollerPWallinHHolstEKnudsenLE 2002 Sunlight-induced DNA damage in human mononuclear cells. FASEB J 16 45 53

32. IoannidisJPA 2007 Genetic and molecular epidemiology. J Epidemiol Community Health 61 757 758

33. PhillipsDHCastegnaroM 1999 Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis 14 301

34. LeekJTScharpfRBBravoHCSimchaDLangmeadB 2010 Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 11 733 739

35. CastaldiPJDahabrehIJIoannidisJP 2011 An empirical assessment of validation practices for molecular classifiers. Brief Bioinform 12 189 202

36. AltmanDGRoystonP 2000 What do we mean by validating a prognostic model? Stat Med 4 453 473

37. CaporasoNE 2002 Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol Biomarkers Prev 11 1544 1549

38. VainioH 2004 Genetic biomarkers and occupational epidemiology – recollections, reflections and reconsiderations. Scand J Work Environ Health 30 1 3

39. MoherDSchulzKFSimeraIAltmanDG 2010 Guidance for developers of health research reporting guidelines. PLoS Med 7 e1000217 doi:10.1371/journal.pmed.1000217

40. SimeraIAltmanDGMoherDSchulzKFHoeyJ 2008 Guidelines for reporting health research: the EQUATOR network's survey of guideline authors. PLoS Med 5 e139 doi:10.1371/journal.pmed.0050139

41. SimeraIMoherDHoeyJSchulzKFAltmanDG 2010 A catalogue of reporting guidelines for health research. Eur J Clin Invest 40 35 53

42. VineisPPereraF 2007 Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol Biomarkers Prev 16 1954 1965

43. AtkinsonAJColburnWADeGruttolaVGDeMetsDLDowningGJ 2001 Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 89 95

44. DecordierIVandeLoockKKirsch-VoldersM 2010 Phenotyping for DNA repair capacity. Mutat Res 705 107 129

45. IoannidisJPTzoulakiI 2010 What makes a good predictor? the evidence applied to coronary artery calcium score. JAMA 16 1646 1647

46. RileyRDSauerbreiWAltmanDG 2009 Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 100 1219 1229

47. SigounasDETatsioniAChristodoulouDKTsianosEVIoannidisJP 2011 New prognostic markers for outcome of acute pancreatitis: overview of reporting in 184 studies. Pancreas 40 522 532

48. GalloVKhanAGonzalesCPhillipsDHSchoketB 2008 Validation of biomarkers for the study of environmental carcinogens: a review. Biomarkers 13 505 534

49. VineisPGalloV 2007 Epidemiological Concepts of Validation of Biomarkers for the Identification/Quantification of Environmental Carcinogenic Exposures Poland ECNIS

50. VineisPMatulloGBerwickM 2005 Molecular epidemiology. AhrensWPigeotI Handbook of Epidemiology Berlin & Heidelberg Springer 1111 1138

51. KristensenP 1992 Bias from nondifferential but dependent misclassification of exposure and outcome. Epidemiology 3 210 215

52. VineisP 1997 Sources of variation in biomarkers. IARC Sci Publ 142 59 71

53. VahakangasK 2004 Ethical aspects of molecular epidemiology of cancer. Carcinogenesis 25 465 471